Opthea Ltd (OPT AU): Lead Asset for Highly Prevalent Retinal Disease Moving Toward Commercialization
Opthea’s OPT-302 is in phase 3 trial for wet AMD. While we are upbeat about the multi-billion-dollar market opportunity of OPT-302, the company’s...
220 Views
Opthea Limited - Eyeing the Global Opportunity in Retinal Diseases
Opthea Limited Eyeing the global opportunity in retinal diseases Opthea Ltd (ASX:OPT) is a clinical-stage biotechnology company focused on...
822 Views
Index Rebalance & ETF Flow Recap: HSI, HSCEI, HSTECH, HSCI, S&P/ASX, SET50, LIC, SBI Sumishin, Crown
This recap highlights Insights covering Asian index rebalances (announcements/ forecasts/ IPO Fast Entry/ M&A driven changes). We also highlight...
481 Views
Paradigm Biopharmaceuticals (PAR AU): Concerns on First Potentially Commercialized Product
The company's dependence on a single molecule makes it a risky bet. Moreover, the inherent safety concern of the lead candidate may limit its...
244 Views
ASX100/200/300 Index Rebalance Preview (March 2022): A Lot Happening From Now to March
There will be many changes to the ASX100/200/300 indices from now to March due to M&A activity & price moves. Plus a large funding trade following...
1k Views